Scientific journal of Research studies in Future Basic Sciences and medical sciences, 2024, Vol. 2, No. 1, pp. 84-97

Scientific journal of Research studies

in Future Basic Sciences and medical sciences

www.journalhi.com/sci/

Gut Microbiome and Treatment Response in Autoimmune Hepatitis: A Review of Mechanisms and Clinical Evidence

Mohammad Karami Horestani [1,*]

1- Assistant Professor of Gastroenterology and Hepatology. Department of Internal Medicine, Clinical Research Development Unit, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord. Email: karami.m@skums.ac.ir

* Corresponding Author

Abstract

Autoimmune hepatitis is a chronic immune-mediated liver disease in which treatment response varies substantially among patients. Increasing evidence indicates that gut microbiome dysbiosis may influence disease activity and therapeutic response through the gut-liver axis. This review examines the mechanisms linking microbial alterations with treatment response, focusing on intestinal barrier dysfunction, microbial metabolites, T-cell regulation, and inflammatory signaling. Available evidence suggests that dysbiosis may increase intestinal permeability, facilitate microbial translocation, and promote hepatic inflammation. Microbiome-derived metabolites may also regulate immune tolerance and inflammatory responses through interactions with immune signaling pathways. Experimental studies indicate that modulation of the gut microbiome can alter autoimmune hepatic inflammation and may modify responses to immunosuppressive treatment. However, clinical evidence in humans remains limited and heterogeneous, and differences in microbiome composition, treatment exposure, and study methodology complicate direct comparisons. Current evidence therefore supports the gut microbiome as a promising mechanistic and translational target, but not yet as an established biomarker for treatment selection or response prediction. Future longitudinal clinical studies integrating microbiome profiles, microbial metabolites, immune parameters, and standardized treatment outcomes are needed to determine its potential role in personalized management of autoimmune hepatitis.

Keywords: Autoimmune hepatitis; Gut microbiome; Dysbiosis; Treatment response; Gut-liver axis

1- Introduction

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease characterized by loss of immune tolerance toward hepatic antigens, persistent hepatocellular injury, autoantibody production, and abnormalities in immunoglobulin G. The clinical course is heterogeneous, ranging from asymptomatic biochemical abnormalities to progressive liver injury and cirrhosis. Although immunosuppressive therapy remains the principal therapeutic strategy, achieving sustained biochemical remission is not uniform across patients. This variability has increased interest in biological mechanisms that may influence disease activity and therapeutic response beyond conventional clinical and serological factors.

The gut microbiome has emerged as an important component of the gut-liver axis and is increasingly implicated in the development and progression of AIH. Experimental and clinical evidence indicates that AIH is associated with alterations in microbial composition and function, including changes in bacterial communities involved in immune regulation and intestinal homeostasis [3,7,8]. These alterations may affect hepatic inflammation through several interconnected mechanisms, including disruption of intestinal barrier integrity, altered microbial metabolite production, and modulation of innate and adaptive immune responses [6,11].

Intestinal barrier dysfunction is particularly relevant because increased permeability can facilitate the passage of microbial products into the portal circulation. Exposure of hepatic immune cells to these microbial signals may activate inflammatory pathways and amplify autoimmune responses. Experimental studies have linked microbiome-associated alterations to signaling mechanisms involving Toll-like receptor 4, nuclear factor-kappa B, and the NLRP3 inflammasome, providing a mechanistic connection between intestinal dysbiosis and hepatic inflammation [5,6].

The microbiome may also influence AIH through its interaction with adaptive immunity. Changes in microbial communities can affect the differentiation and activity of T-cell populations involved in immune tolerance and autoimmune inflammation. Experimental evidence has identified interactions involving follicular helper T cells and other T-cell subsets, suggesting that microbial alterations may modify the immunological environment in which hepatic autoimmunity develops and persists [2,4,10]. In addition, microbiota-derived metabolites, particularly products of tryptophan metabolism, can influence immune-cell function through metabolite-sensitive pathways such as the aryl hydrocarbon receptor, thereby providing another potential mechanism through which intestinal microbial activity may affect hepatic inflammation [12].

The relationship between the gut microbiome and treatment response is especially relevant because microbiome-directed interventions have produced changes in experimental autoimmune hepatitis and, in some settings, have enhanced the effects of immunosuppressive treatment. For example, modulation of Lactobacillus populations has been associated with improved effects of prednisone in experimental and clinical contexts, suggesting that specific microbial alterations may interact with established therapeutic pathways [2]. Other experimental interventions, including probiotics and synbiotics, have similarly

demonstrated effects on intestinal microbiota, barrier function, and hepatic inflammatory signaling [1,5].

Despite these advances, important uncertainties remain. Much of the mechanistic evidence originates from animal models, whereas human evidence remains comparatively limited. Moreover, differences in patient characteristics, treatment exposure, dietary factors, microbiome analytical methods, and definitions of treatment response make direct comparison between studies difficult [7,8,13]. Consequently, determining whether microbiome alterations merely accompany disease activity or actively contribute to differences in therapeutic response remains an important research question.

This review therefore examines the available evidence concerning the relationship between gut microbiome dysbiosis and treatment response in AIH, with particular emphasis on intestinal barrier integrity, microbial metabolites, immune regulation, inflammatory signaling, and microbiome-targeted interventions. By integrating mechanistic findings with available clinical evidence, the review seeks to clarify the current biological rationale for considering the gut microbiome as a potential component of future approaches to individualized AIH management.

2- Problem Statement

Despite increasing recognition of the gut microbiome as an important regulator of the gut-liver axis, its specific contribution to treatment response in autoimmune hepatitis remains insufficiently characterized. Current therapeutic strategies for autoimmune hepatitis primarily target systemic and hepatic immune activation, whereas the intestinal microbial environment is rarely incorporated into treatment-response assessment. This creates an important gap because microbial dysbiosis may influence several biological processes directly relevant to disease persistence, including intestinal permeability, microbial translocation, immune-cell differentiation, and production of bioactive metabolites [6,7,11].

An important unresolved issue is whether dysbiosis represents a consequence of hepatic inflammation and immunosuppressive treatment or whether specific microbial alterations actively participate in maintaining autoimmune activity and modifying therapeutic outcomes. Experimental evidence supports a bidirectional relationship between microbial disturbances and autoimmune liver inflammation. Alterations in microbial communities have been associated with impaired immune tolerance and increased hepatic inflammatory responses, while manipulation of the microbiome can modify disease severity in experimental models [3-5]. These observations provide a biological basis for investigating the microbiome beyond its potential role as a passive disease marker.

The treatment-response dimension introduces an additional level of complexity. Immunosuppressive therapy can alter the intestinal environment, while microbial composition and microbial metabolites may, in turn, influence immune pathways targeted by treatment. Findings concerning Lactobacillus and prednisone provide an example of this interaction, suggesting that changes in the intestinal microbial environment may modify the immunological effects of established therapy [2]. However, available evidence does not yet establish whether particular microbial profiles consistently predict biochemical remission, incomplete response, or relapse in patients with AIH.

Another major problem is the heterogeneity of the existing evidence. Studies differ considerably in experimental design, microbiome assessment, disease models, treatment interventions, and measured outcomes. Evidence derived from animal models has provided substantial mechanistic information, but its direct translation to human AIH remains uncertain [1,4,5,9]. Similarly, reviews and emerging clinical investigations have identified potentially informative microbial signatures, but the reproducibility and clinical applicability of these signatures require further validation [7,8,13].

Therefore, the central problem addressed by this review is the absence of a sufficiently integrated understanding of how gut microbial dysbiosis may influence treatment response in autoimmune hepatitis. Clarifying the relationships among microbial composition, intestinal barrier function, microbial metabolites, immune regulation, and therapeutic response may help define the biological pathways connecting the intestinal ecosystem with clinical disease behavior. It may also identify priorities for future longitudinal studies designed to determine whether microbiome-derived characteristics can eventually complement established clinical and biochemical indicators of treatment response.

3- Methods

3.1. Study Design

This study was designed as a structured narrative review to examine the relationship between gut microbiome alterations and treatment response in autoimmune hepatitis (AIH). The methodological framework was developed to integrate mechanistic evidence with available clinical findings while maintaining a clear distinction between experimental and human evidence. The review focused specifically on the biological pathways through which gut microbial dysbiosis may influence hepatic inflammation and therapeutic response, including intestinal barrier dysfunction, microbial translocation, immune-cell regulation, microbial metabolites, and inflammatory signaling.

The scope of the review was deliberately restricted to autoimmune hepatitis and its relationship with the gut microbiome. Studies addressing other chronic liver diseases were not incorporated into the evidence synthesis unless their findings were directly relevant to a mechanism examined in the selected AIH literature. The final evidence base consisted exclusively of the 13 predetermined English-language peer-reviewed publications selected for this review.

3.2. Evidence Selection

The evidence base was established before preparation of the main sections of the article in order to maintain consistency in citation numbering and prevent selective expansion of the reference list during manuscript development. The selected publications were published between 2021 and 2025 and comprised experimental studies, mechanistic investigations, clinical evidence, and focused scientific reviews addressing the gut microbiome in AIH.

The selected studies were evaluated according to their relevance to at least one of the following domains: microbial dysbiosis, intestinal permeability and barrier integrity, gut-liver immune communication, T-cell regulation, microbial metabolites, inflammatory signaling, microbiome-targeted interventions, or treatment response. Studies with a predominantly mechanistic focus were used to explain biological pathways, whereas studies involving therapeutic interventions or human populations were considered when discussing potential clinical implications [1-13].

3.3. Data Extraction Framework

Information was conceptually extracted from each selected publication according to a predefined framework. The principal categories included study population or experimental model, microbiome-related exposure or intervention, principal microbial alterations, biological pathway investigated, immune or inflammatory outcome, treatment-related findings, and major implications for AIH.

For experimental studies, particular attention was given to the relationship between microbiome manipulation and hepatic inflammatory activity. Studies examining probiotics, synbiotics, specific bacterial taxa, or microbiome-associated metabolites were evaluated according to their reported effects on intestinal integrity and immune signaling [1,5,9]. Studies examining immune mechanisms were assessed with emphasis on T-cell populations and signaling pathways potentially linking microbial alterations to hepatic autoimmunity [2-4,10].

3.4. Assessment of Mechanistic Evidence

Mechanistic evidence was organized around the gut-liver axis. Three interconnected biological levels were considered.

The first level involved intestinal homeostasis, particularly changes in microbial composition and intestinal barrier integrity. Evidence indicating increased intestinal permeability or disruption of microbial equilibrium was considered relevant because these alterations may increase exposure of the liver to microbial components [6,11].

The second level involved microbial products and metabolites. Particular consideration was given to microbiota-derived metabolites capable of influencing immune-cell activity. Tryptophan-derived microbial metabolites were examined as an example of how intestinal microbial metabolism may regulate immune responses through specific host signaling pathways [11,12].

The third level involved hepatic and systemic immune responses. Evidence concerning T-cell differentiation, inflammatory signaling, and innate immune activation was synthesized to determine how microbiome alterations could potentially influence autoimmune hepatic injury [2,4,5,10].

3.5. Evaluation of Treatment-Related Evidence

Treatment-related findings were examined separately from general disease mechanisms. Particular attention was given to evidence concerning interactions between microbiome composition and immunosuppressive treatment. The effects of Lactobacillus-associated microbiome modulation on prednisone treatment were considered in relation to immune regulation and follicular helper T-cell activity [2].

Evidence from probiotic and synbiotic interventions was also examined to determine whether manipulation of the intestinal microbial environment could alter hepatic inflammation or pathways associated with treatment response [1,5]. Berberine-mediated microbiome modulation was considered as an additional experimental example of microbiome-associated alteration of autoimmune hepatic inflammation [9].

Because several of these investigations were performed in experimental models, their findings were not treated as equivalent to evidence demonstrating clinical efficacy in human patients. This distinction was maintained throughout the synthesis to avoid extrapolating experimental observations directly to clinical treatment recommendations.

3.6. Evidence Synthesis

The extracted evidence was synthesized narratively rather than through quantitative meta-analysis. This approach was selected because of substantial methodological heterogeneity among the included studies, including differences in experimental models, microbial assessment methods, interventions, immune outcomes, and definitions of treatment response.

The synthesis was organized into five principal domains: microbial dysbiosis and AIH pathogenesis; intestinal barrier dysfunction and microbial translocation; microbiome-mediated immune regulation; microbial metabolites and inflammatory signaling; and potential relationships between microbiome modulation and treatment response.

Evidence was interpreted according to its level of biological and clinical relevance. Mechanistic findings were used to establish plausible pathways, whereas human evidence was given greater consideration when discussing potential clinical applicability. Reviews were used to contextualize the primary literature rather than to substitute for primary evidence [7,8,11,13].

3.7. Development of Tables and Figures

Tables and figures were designed as evidence-synthesis tools rather than as representations of newly generated experimental data. The tables summarize the characteristics and principal findings of the selected publications, while the proposed multidimensional figures integrate relationships among microbial dysbiosis, intestinal barrier integrity, microbial metabolites, immune regulation, and treatment response.

Where numerical or categorical information is presented, it is derived from the selected publications. No hypothetical patient-level observations or artificially generated experimental results are introduced. This approach allows the visual components of the review to illustrate relationships identified in the published evidence while preserving the distinction between reported findings and conceptual interpretation.

3.8. Methodological Limitations

The principal methodological limitation of this review is the restricted number of eligible publications and the heterogeneity of the available evidence. The evidence base contains a substantial proportion of experimental studies, whereas longitudinal clinical investigations directly

evaluating microbiome profiles against standardized treatment-response outcomes remain limited [1,4,5,9].

Another limitation is the inherent variability of gut microbiome composition across individuals. Dietary patterns, medication exposure, geographic factors, age, and other host characteristics may influence microbial profiles and complicate identification of disease-specific or treatment-specific microbial signatures. Consequently, associations observed in individual studies should not automatically be interpreted as universally applicable biomarkers.

Despite these limitations, restricting the review to a predefined set of peer-reviewed publications and maintaining a structured evidence-extraction framework provides a consistent basis for examining the current relationship between gut microbiome biology and treatment response in AIH.

4- Results

4.1. Gut Microbiome Dysbiosis and the Gut-Liver Axis in Autoimmune Hepatitis

The integrated evidence indicates that gut microbiome dysbiosis is closely associated with the biological processes involved in autoimmune hepatitis. Rather than representing an isolated alteration in bacterial composition, dysbiosis appears to involve interconnected changes in microbial ecology, intestinal barrier function, immune regulation, and hepatic inflammatory signaling. This relationship provides a mechanistic basis for considering the intestinal microbiome as an important component of the pathophysiological network underlying autoimmune hepatitis [3,7,8].

A consistent feature emerging from the available evidence is disruption of the normal interaction between intestinal microorganisms and host immune homeostasis. Under physiological conditions, the intestinal microbiome contributes to epithelial integrity, metabolic signaling, immune maturation, and maintenance of tolerance. Disturbance of this equilibrium may alter the interaction between microbial communities and the intestinal immune system, creating conditions that favor persistent inflammatory signaling. In autoimmune hepatitis, such alterations may extend beyond the intestinal compartment because microbial products and metabolites can reach the liver through the portal circulation.

The gut-liver anatomical connection provides an important explanation for this relationship. The liver receives a substantial proportion of its blood supply from the portal circulation, exposing hepatic immune cells to metabolites and microbial-derived molecular signals originating in the intestine. When intestinal barrier integrity is compromised, increased quantities of microbial components may cross the epithelial barrier. Recognition of these components by innate immune receptors can activate downstream inflammatory pathways and potentially amplify hepatic immune responses [5,6].

The available evidence further suggests that dysbiosis should not be interpreted solely in terms of the presence or absence of individual bacterial taxa. Functional consequences may be more relevant than taxonomic changes alone. Alterations in microbial metabolic activity can modify the availability of short-chain fatty acids, bile-acid derivatives, tryptophan metabolites, and other bioactive compounds capable of influencing immune-cell behavior. Consequently, two individuals with apparently similar taxonomic profiles may potentially exhibit different immunological consequences because of differences in microbial function and metabolite production [11,12].

Another important finding is the interaction between microbial alterations and adaptive immunity. The intestinal microbiome can influence the differentiation and activity of several T-cell populations involved in immune tolerance and inflammatory responses. Disturbances in these interactions may shift the balance between regulatory mechanisms and effector immune activity. Evidence involving follicular helper T cells and other T-cell populations suggests that microbiome-associated immune modulation may represent one pathway through which intestinal alterations become linked to hepatic autoimmunity [2,4,10].

Table 1. Principal Biological Components Linking Gut Microbiome Dysbiosis With Autoimmune Hepatitis

Biological component	Alteration associated with dysbiosis	Potential consequence	Relevance to autoimmune hepatitis
Microbial community structure	Disturbance of intestinal microbial equilibrium	Altered microbial-host interactions	May contribute to loss of immune homeostasis
Intestinal epithelial barrier	Increased permeability and barrier dysfunction	Greater passage of microbial products	May increase hepatic inflammatory stimulation
Microbial-derived molecules	Altered exposure to microbial components	Activation of innate immune receptors	Potential amplification of hepatic inflammation
Microbial metabolites	Changes in metabolite production and availability	Modification of immune-cell signaling	May influence inflammatory and regulatory responses
T-cell regulation	Altered interaction between microbiota and adaptive immunity	Changes in T-cell differentiation and activity	Potential modulation of autoimmune activity
Hepatic inflammatory signaling	Increased activation of inflammatory pathways	Sustained immune-mediated hepatocellular injury	May contribute to disease persistence
Therapeutic interaction	Microbiome-dependent modification of immune pathways	Potential alteration of treatment effects	May partly explain variability in treatment response

These observations support a multidimensional model in which dysbiosis, intestinal permeability, microbial metabolites, and immune activation form a connected biological system rather than independent phenomena. Within this model, dysbiosis may contribute to increased epithelial permeability; barrier dysfunction may increase

exposure to microbial products; microbial products may activate innate immune signaling; and altered microbial metabolites may influence adaptive immune regulation. The resulting inflammatory environment may then contribute to persistence or amplification of hepatic autoimmune activity.

The integrated pattern presented in Table 1 indicates that the relationship between the intestinal microbiome and autoimmune hepatitis is best understood as a network of interconnected processes. The intestinal barrier represents a critical interface within this network because it determines the extent to which microbial products and metabolites can influence systemic and hepatic immunity. At the same time, immune regulation represents a downstream mechanism through which microbial alterations may become clinically relevant.

The available experimental evidence also indicates that modifying the intestinal microbial environment can influence the severity of autoimmune hepatic inflammation. Interventions involving probiotics, synbiotics, and other microbiome-modulating strategies have been associated with changes in intestinal microbial composition, barrier function, inflammatory signaling, or immune responses [1,5,9]. These observations strengthen the biological plausibility of a causal relationship, although the extent to which such findings can be translated into routine human treatment remains uncertain.




Figure 1. Proposed Multidimensional Gut Microbiome–Liver Interaction in Autoimmune Hepatitis

Figure 1 illustrates that treatment response should not be viewed as a direct consequence of a single microbial alteration. Instead, it may emerge from interactions among microbial ecology, epithelial integrity, metabolic activity, and immune regulation. This interpretation is particularly relevant when considering why identical immunosuppressive regimens may produce different biological responses among patients.

The findings therefore support the concept that gut microbiome dysbiosis is biologically connected to autoimmune hepatitis through multiple complementary pathways. However, the current evidence does not establish a single microbial signature that can independently define disease activity or predict therapeutic response. The relationship appears to be dependent on the combined effects of microbial composition, microbial function, host immunity, and intestinal barrier status [7,8,11,13].

4.2. Intestinal Barrier Dysfunction and Microbial Translocation

The available evidence indicates that intestinal barrier integrity is a central intermediary between gut microbiome alterations and hepatic immune activation in autoimmune hepatitis. Under physiological conditions, the intestinal epithelium provides a selective barrier that permits nutrient absorption while limiting systemic exposure to potentially immunogenic microbial components. Dysbiosis can disrupt this equilibrium through alterations in epithelial function, microbial-host signaling, and local inflammatory processes. Increased intestinal permeability may consequently facilitate the movement of bacterial components and other microbial products toward the portal circulation, creating a continuous interface between intestinal microbial activity and hepatic immunity [6,11].

The importance of this mechanism is supported by experimental evidence showing that disruption of intestinal microbial homeostasis is accompanied by impaired barrier function and increased susceptibility to autoimmune hepatic inflammation. These observations suggest that microbial dysbiosis and barrier dysfunction may operate as mutually reinforcing processes. Changes in microbial communities can compromise epithelial homeostasis, while barrier disruption can alter the intestinal environment in ways that further favor microbial imbalance [3,6].

From a mechanistic perspective, increased permeability may expose hepatic immune cells to microbial-associated molecular patterns capable of activating innate immune receptors. This interaction can stimulate inflammatory signaling pathways, including pathways involving Toll-like receptor 4, nuclear factor-kappa B, and the NLRP3 inflammasome. Persistent activation of these pathways may increase the inflammatory tone within the liver and contribute to the maintenance of autoimmune injury [5,6].

Table 2. Relationship Between Intestinal Barrier Dysfunction and Hepatic Immune Activation

Process	Biological alteration	Potential downstream effect
Microbial dysbiosis	Altered intestinal microbial equilibrium	Disruption of host-microbiome homeostasis
Epithelial dysfunction	Reduced barrier integrity	Increased intestinal permeability
Microbial translocation	Greater passage of microbial components	Increased portal exposure to microbial signals
Innate immune activation	Stimulation of microbial-sensing receptors	Activation of inflammatory pathways
Hepatic inflammation	Increased inflammatory signaling	Amplification of autoimmune liver injury
Persistent immune activation	Continued exposure to inflammatory stimuli	Potential contribution to chronic disease activity

The gut-liver connection is particularly relevant because the portal circulation provides a direct route through which intestinally derived molecules can reach hepatic tissue. Consequently, changes occurring within the intestinal environment do not necessarily remain localized to the gastrointestinal tract. Altered microbial products entering the portal circulation may interact with Kupffer cells, hepatic antigen-presenting cells, and other components of the hepatic immune system. This provides a plausible

biological pathway linking intestinal barrier dysfunction with hepatic inflammatory responses.

As shown in Table 2, intestinal permeability provides a functional bridge between microbial alterations and hepatic inflammation. This distinction is important because taxonomic changes in the microbiome alone may not fully explain their clinical significance. The biological effect of dysbiosis may depend substantially on whether microbial alterations are accompanied by impaired epithelial integrity and increased exposure of the liver to microbial signals.

Experimental intervention studies provide additional support for this interpretation. Probiotic and synbiotic approaches have been associated with improvements in intestinal microbial balance and reductions in inflammatory activity in experimental models of autoimmune hepatitis [1,5]. Although these findings do not establish clinical efficacy in patients, they indicate that intestinal barrier function may be modifiable and may represent an intermediate therapeutic target connecting microbiome manipulation with hepatic immune regulation.

The relationship between barrier integrity and treatment response is also potentially important. Immunosuppressive treatment primarily acts on immune pathways involved in hepatic inflammation, whereas intestinal barrier dysfunction may provide a continuing source of immune stimulation. If microbial products continue to cross a compromised intestinal barrier, hepatic inflammatory pathways may remain exposed to signals that counterbalance or complicate the effects of immunosuppression. This provides a plausible explanation for why microbiome status could influence the biological context in which treatment operates, although direct clinical confirmation remains limited.




Figure 2. Multidimensional Relationship Between Gut Barrier Dysfunction and Treatment Response

Figure 2 emphasizes that intestinal barrier dysfunction may function as an intermediate biological mechanism rather than simply an accompanying feature of autoimmune hepatitis. The model also illustrates why microbiome-related factors may be relevant to therapeutic response even when the treatment itself does not directly target intestinal microorganisms.

An additional consideration is that microbial metabolites may influence barrier function independently of microbial translocation. Changes in microbial metabolism can modify concentrations of biologically active compounds capable of affecting epithelial cells and immune populations. Tryptophan-derived microbial metabolites, for example, can participate in immune regulation through activation of the aryl hydrocarbon receptor, creating a mechanistic connection between microbial metabolism and host immune homeostasis [11,12].

Taken together, the evidence indicates that intestinal barrier dysfunction is one of the most biologically plausible pathways connecting gut microbiome dysbiosis with autoimmune hepatitis. Nevertheless, the directionality of this relationship cannot yet be established with certainty in human disease. Hepatic inflammation, medication exposure, diet, and other host factors may themselves influence intestinal permeability and microbial composition. Longitudinal studies are therefore required to determine whether barrier dysfunction precedes changes in disease activity and whether restoration of intestinal integrity is associated with improved therapeutic outcomes.

4.3. Microbial Metabolites and Immune Regulation

Gut microbiome activity extends beyond the composition of bacterial communities. Microorganisms continuously transform dietary and endogenous substrates into metabolites that can influence epithelial integrity, immune-cell differentiation, and inflammatory signaling. Consequently, alterations in microbial metabolism may represent an important mechanism through which dysbiosis affects autoimmune hepatitis. Current evidence particularly highlights the potential importance of microbiota-derived metabolites in regulating the balance between inflammatory and tolerogenic immune responses [11,12].

Among these metabolites, compounds generated through microbial transformation of tryptophan have attracted increasing attention. Tryptophan-derived microbial metabolites can interact with host receptors involved in immune regulation, particularly the aryl hydrocarbon receptor. Activation of this receptor can influence T-cell behavior and modify inflammatory responses, providing a direct molecular link between microbial metabolism and immune function [12].

This mechanism is relevant to autoimmune hepatitis because inappropriate activation of effector immune pathways and insufficient regulatory control are central features of autoimmune liver injury. Changes in the availability or activity of microbiota-derived metabolites may therefore alter the threshold at which immune activation occurs. Rather than acting as isolated inflammatory mediators, these metabolites may contribute to a broader regulatory network involving intestinal epithelial cells, antigen-presenting cells, and T-cell populations.

The relationship between the microbiome and T-cell regulation is also supported by evidence involving follicular helper T cells. Microbiome-associated changes have been linked to alterations in immune-cell populations that participate in the maintenance or amplification of autoimmune responses [2,10]. These findings suggest that intestinal microbial signals may influence hepatic autoimmunity indirectly by modifying systemic immune-cell differentiation and function.

Experimental studies further indicate that microbial alterations can influence autoimmune hepatitis through interactions between microbial communities and hepatic immune pathways. Changes in the intestinal microbiota have been associated with modulation of inflammatory

signaling and T-cell-mediated hepatic injury, suggesting that microbiome composition and microbial function may jointly contribute to the immunological environment of the disease [3-5].

Table 3. Microbial Metabolite and Immune-Regulatory Pathways Relevant to Autoimmune Hepatitis

Microbiome-related factor	Principal biological interaction	Potential immune consequence	Relevance to AIH
Tryptophan-derived metabolites	Activation of aryl hydrocarbon receptor	Modulation of T-cell responses	Potential regulation of hepatic inflammation
Altered microbial metabolism	Modified metabolite availability	Changes in immune signaling	May influence immune tolerance
Microbial components	Interaction with innate immune receptors	Activation of inflammatory pathways	Potential amplification of hepatic injury
Microbiome–T-cell interaction	Modification of T-cell differentiation	Altered effector/regulatory balance	Potential contribution to autoimmune activity
Microbiome-associated signaling	Interaction with hepatic inflammatory pathways	Sustained inflammatory activation	Possible influence on treatment response

Table 3 demonstrates that microbial metabolites provide a functional dimension that cannot be captured through taxonomic profiling alone. A microbiome profile may identify changes in bacterial abundance, but the resulting biological effects may depend on the metabolic capabilities of the microbial community. This distinction is particularly important when considering the potential use of the microbiome as a biomarker because microbial composition and microbial function do not necessarily change in parallel.

The interaction between microbial metabolites and immune regulation may also help explain variability in treatment response. Immunosuppressive therapy is intended to reduce pathogenic immune activation, but the immune environment in which these drugs act is influenced by multiple endogenous signals. Microbiome-derived metabolites can potentially alter this environment by affecting immune-cell activation and differentiation. Thus, differences in microbial metabolic activity between patients may contribute to differences in the immunological response to otherwise similar treatment strategies. At present, however, this relationship remains mechanistically plausible rather than clinically established.

The experimental evidence provides an important basis for this interpretation. Microbiome-modifying interventions have produced changes in inflammatory activity in experimental autoimmune hepatitis, while specific microbial or metabolite-related pathways have been associated with altered immune responses [1,5,9,12]. These findings collectively indicate that the microbiome is not simply a passive indicator of disease status but may participate actively in the regulation of immune processes relevant to hepatic autoimmunity.




Figure 3. Integrated Microbiome–Metabolite–Immune Signaling Model

Figure 3 illustrates the convergence of microbial metabolic and immune pathways. The model indicates that dysbiosis may influence autoimmune hepatitis through both direct inflammatory signaling and indirect regulation of immune-cell behavior. The two pathways are not mutually exclusive and may operate simultaneously within the gut-liver axis.

Another relevant observation is that microbial modulation can produce different biological outcomes depending on the intervention and the underlying microbial environment. Probiotic and synbiotic approaches have demonstrated beneficial effects in experimental models, but these effects cannot be assumed to result from a single bacterial species or metabolite [1,5]. Instead, restoration of microbial ecological balance, improvement of barrier function, and alteration of immune signaling may occur concurrently.

Berberine-related experimental findings provide a further example of the potential connection between microbiome modulation and hepatic inflammation. Changes in the gut microbial environment were associated with attenuation of experimental autoimmune hepatitis, supporting the broader concept that modifying microbial ecology can influence disease-associated immune pathways [9]. Nevertheless, such findings should be interpreted cautiously because experimental interventions may affect multiple biological systems simultaneously.

The current evidence therefore supports a model in which microbial metabolites act as intermediary signals connecting intestinal microbial activity with host immune regulation. This model strengthens the biological rationale for investigating microbiome-derived metabolites alongside conventional microbial composition measures. However, the clinical value of individual metabolites or metabolite profiles as predictors of treatment response remains insufficiently established.

4.4. Gut Microbiome Modulation and Treatment Response

The available evidence suggests that the gut microbiome may influence treatment response in autoimmune hepatitis through interactions with immunological pathways targeted by conventional therapy. This relationship is particularly relevant because the clinical objective of treatment is not simply suppression of inflammation, but achievement and maintenance of

biochemical remission while minimizing relapse and treatment-related complications. Variability in response may therefore reflect differences in the biological environment in which immunosuppressive therapy operates.

One of the most direct lines of evidence concerns the interaction between microbiome modulation and prednisone treatment. Experimental findings indicate that Lactobacillus-associated modification of the intestinal microbiota can enhance the effects of prednisone and is accompanied by changes in follicular helper T-cell activity [2]. This observation provides a mechanistic basis for the hypothesis that intestinal microorganisms may influence the efficacy of established immunosuppressive treatment through modulation of adaptive immunity.

Table 4. Evidence Linking Microbiome Modulation With Treatment-Related Outcomes in Autoimmune Hepatitis

Microbiome-related approach	Principal target or mechanism	Reported biological effect	Potential relevance to treatment response
Probiotic modulation	Microbial composition and intestinal permeability	Reduction of experimental hepatic inflammation	May create a more favorable immune environment
Lactobacillus-associated modulation	Gut microbiota and follicular helper T cells	Enhancement of prednisone-associated effects	Direct mechanistic relevance to immunosuppressive therapy
Synbiotic intervention	Gut-liver axis and inflammatory signaling	Suppression of TLR4/NF-κB/NLRP3 activity	Potential complementary therapeutic mechanism
Microbiome-modulating compounds	Alteration of microbial ecology	Reduced experimental hepatic inflammation	Supports microbiome as a therapeutic target
Microbial metabolite modulation	Immune-cell signaling	Regulation of inflammatory and tolerogenic pathways	Potential influence on therapeutic responsiveness

The potential importance of this interaction extends beyond a single bacterial genus. Probiotic interventions have been associated with alterations in gut microbial composition and intestinal permeability, accompanied by attenuation of autoimmune hepatic inflammation [1]. Similarly, synbiotic intervention has been linked to modulation of the gut microbiota-liver axis and suppression of inflammatory signaling involving TLR4, NF-κB, and NLRP3 [5]. Together, these findings suggest that microbiome-directed interventions may influence several biological pathways simultaneously rather than acting through a single immune mechanism.

Table 4 demonstrates that the available treatment-related evidence is heterogeneous. Some studies directly examine interactions between microbiome modulation and an established immunosuppressive agent, whereas others evaluate microbiome-targeted interventions independently. These two types of evidence should not be considered equivalent. The former provides greater relevance to treatment-response mechanisms, while the latter primarily demonstrates that microbial manipulation can alter biological pathways involved in autoimmune hepatic inflammation.

The relationship between the microbiome and corticosteroid response may involve multiple levels of immune regulation. Corticosteroids influence a broad range of inflammatory processes, including transcriptional regulation of cytokines and modulation of immune-cell activity. If microbiome-derived signals alter the baseline activation state or differentiation of immune populations, the same pharmacological exposure could theoretically produce different downstream effects in different microbial environments. Evidence involving follicular helper T cells provides one potential example of such microbiome–immune interaction [2].

At the same time, the microbiome itself may be affected by treatment. Immunosuppressive drugs, changes in diet, disease severity, and concurrent medications can modify the intestinal microbial environment. Consequently, the observed relationship between dysbiosis and treatment response may be bidirectional. Treatment may alter microbial composition, while microbial alterations may influence the immunological consequences of treatment. This bidirectional relationship complicates interpretation of cross-sectional microbiome studies.




Figure 4. Bidirectional Relationship Between Gut Microbiome and Immunosuppressive Treatment

Figure 4 illustrates why treatment response cannot necessarily be interpreted as a one-directional relationship between microbiome status and therapeutic efficacy. The microbiome may influence treatment-associated immune responses, while treatment itself may modify the intestinal environment. Longitudinal assessment is therefore particularly important for determining temporal relationships.

Evidence from microbiome-modulating interventions also suggests that restoration of intestinal homeostasis may influence disease activity through several interconnected pathways. Probiotic treatment has been associated with improvements in microbial balance and intestinal permeability, whereas synbiotic approaches have demonstrated effects on inflammatory signaling within the gut-liver axis [1,5]. These findings support the concept of microbiome modulation as a possible complementary strategy rather than an established replacement for standard immunosuppressive therapy.

Experimental evidence involving berberine further supports the potential of microbiome-associated interventions to modify autoimmune hepatic inflammation [9]. However, the observed effects cannot necessarily be attributed exclusively to changes in bacterial composition because such interventions may also influence host metabolic and inflammatory pathways directly. This represents an important consideration when interpreting microbiome-targeted treatment studies.

The evidence also suggests that treatment response may depend more on microbial function than on the abundance of individual bacterial taxa. Changes in microbial metabolites can affect immune signaling independently of taxonomic composition, while barrier integrity can determine the degree to which microbial products reach hepatic tissue [11,12]. Therefore, future treatment-response models may need to integrate microbial composition, microbial function, intestinal permeability, and immune phenotypes rather than relying on a single microbial marker.

A further limitation concerns the scarcity of standardized clinical endpoints across the available evidence. Experimental studies frequently use biochemical or histological indicators of hepatic inflammation, whereas clinical treatment response may involve biochemical remission, normalization of liver enzymes, relapse prevention, and sustained disease control. These differences make direct extrapolation from experimental models to clinical treatment outcomes difficult.

Overall, the current evidence supports a biologically plausible relationship between the gut microbiome and treatment response in autoimmune hepatitis. The strongest mechanistic evidence concerns interactions among microbial modulation, intestinal integrity, T-cell regulation, and inflammatory signaling. However, evidence remains insufficient to establish a validated microbiome-based predictor of therapeutic response. The most appropriate interpretation at present is that the microbiome represents a potentially important modifier of the treatment environment whose clinical predictive value requires prospective validation.

4.5. Clinical Evidence, Microbial Signatures, and Translational Potential

The available clinical evidence suggests that alterations in the gut microbiome are associated with autoimmune hepatitis, but the strength and consistency of this association remain insufficient for routine clinical application. Compared with experimental research, human studies provide a more complex picture because microbial composition is influenced by treatment exposure, dietary patterns, host characteristics, disease severity, and other environmental factors. Consequently, identifying a reproducible microbial signature that independently reflects disease activity or predicts therapeutic response remains challenging [7,8,13].

Current evidence indicates that the microbiome may contain information relevant to the biological state of patients with autoimmune hepatitis. Differences in microbial composition and function have been reported in association with autoimmune hepatic inflammation, supporting the possibility that specific microbial characteristics could eventually contribute to biomarker development [7,13]. However, the presence of a microbial difference does not by itself demonstrate that the altered microbial feature determines treatment response. A clinically useful biomarker would need to demonstrate reproducibility, temporal stability, and an independently validated association with a defined treatment outcome.

This distinction is particularly important because treatment response is dynamic. A microbial profile measured before treatment may differ from the profile observed after initiation of immunosuppressive therapy. If treatment itself changes the microbiome, post-treatment microbial characteristics may represent a consequence of therapeutic exposure rather than a predictor of response. Therefore, longitudinal sampling before, during, and after treatment would provide substantially stronger evidence than a single cross-sectional measurement.

Table 5. Translational Value of Gut Microbiome Findings in Autoimmune Hepatitis

Evidence domain	Current observation	Potential clinical application	Principal limitation
Microbial composition	Disease-associated microbial alterations	Biomarker development	Limited reproducibility across populations
Intestinal barrier function	Association with microbial dysbiosis	Disease-mechanism assessment	Limited standardized clinical measurements
Microbial metabolites	Immune-regulatory activity	Functional biomarkers or therapeutic targets	Incomplete human validation
T-cell–microbiome interactions	Association with immune regulation	Mechanistic stratification of patients	Predominantly mechanistic evidence
Microbiome modulation	Reduction of experimental inflammation	Adjunctive therapeutic development	Limited clinical intervention evidence
Treatment-associated microbial changes	Potential interaction with immunosuppressive therapy	Response monitoring	Directionality remains uncertain

The available mechanistic evidence provides several potential biological explanations for such temporal associations. Microbial dysbiosis may influence intestinal permeability and microbial translocation, while microbial metabolites may modify immune-cell activity and inflammatory signaling [6,11,12]. At the same time, therapeutic interventions may alter immune activity and indirectly affect the intestinal environment. These reciprocal effects make it difficult to determine whether a specific microbial signature represents a cause, consequence, or marker of treatment response.

The information summarized in Table 5 indicates that the translational potential of microbiome research extends across several levels, but each level has distinct limitations. Microbial composition is relatively accessible through

sequencing-based approaches, yet taxonomic variation alone may not adequately represent biological function. Metabolite-based approaches may provide more direct information about microbial activity, but they require standardized analytical methods and validation in well-characterized patient populations.

The distinction between diagnostic and predictive biomarkers is also critical. A microbial pattern associated with autoimmune hepatitis may have diagnostic relevance without predicting whether a patient will respond to corticosteroids or other immunosuppressive agents. Similarly, a microbial alteration associated with active disease may disappear following successful treatment without being responsible for the initial therapeutic response. Current evidence does not yet allow these possibilities to be clearly separated.

The translational significance of microbial signatures is strengthened by experimental evidence demonstrating that manipulation of the microbiome can alter autoimmune hepatic inflammation. Studies involving probiotics, synbiotics, and microbiome-modulating compounds indicate that changes in microbial ecology can be accompanied by alterations in intestinal permeability, immune signaling, and hepatic inflammatory activity [1,5,9]. Such findings provide biological support for therapeutic investigation but do not establish that these interventions improve clinically meaningful outcomes in patients.

An important aspect of future clinical translation is therefore the integration of microbiome data with conventional indicators of treatment response. Rather than replacing established biochemical and clinical assessments, microbial characteristics could potentially provide complementary information. A multidimensional model could incorporate microbial composition, microbial metabolites, intestinal barrier markers, immune-cell phenotypes, treatment exposure, and longitudinal biochemical outcomes.




Figure 5. Translational Pathway From Microbiome Profiling to Personalized Treatment Assessment

Figure 5 illustrates a possible translational framework rather than an established clinical algorithm. Its principal implication is that microbiome information is unlikely to be sufficiently informative when considered independently. Integration with established clinical variables and longitudinal treatment outcomes may be necessary to determine whether microbiome-based measures provide clinically meaningful predictive information.

The human evidence currently supports cautious optimism regarding this possibility. Reviews of the field have identified the gut microbiome as a promising source of diagnostic and therapeutic targets, while more recent work has emphasized the importance of microbial metabolites, intestinal barrier integrity, and immune homeostasis [7,8,11]. Emerging evidence concerning microbial signatures further suggests that microbiome-based approaches may eventually contribute to disease characterization [13]. However, these possibilities require prospective validation before they can be translated into clinical decision-making.

Another consideration is interindividual variability. The gut microbiome is a highly dynamic ecosystem, and microbial profiles can vary substantially between individuals. Geographic environment, diet, medication exposure, and other host-related factors may influence the observed microbial composition. A microbial feature identified in one patient population may therefore have limited predictive value in another population unless its association with treatment response is independently reproduced.

The current evidence consequently supports the use of microbiome profiling primarily as a research and translational tool rather than as an established component of routine treatment selection. The strongest opportunity appears to lie in longitudinal studies that simultaneously measure microbial composition, microbial function, intestinal barrier status, immune phenotypes, and standardized treatment outcomes. Such studies could help determine whether microbiome alterations precede treatment response, emerge as a consequence of therapy, or reflect a combination of both processes.

Taken together, the clinical evidence establishes a plausible association between the gut microbiome and autoimmune hepatitis but does not yet demonstrate a validated microbiome-based predictor of therapeutic response. The transition from mechanistic association to clinical utility will require reproducible microbial signatures, standardized analytical methods, prospective validation, and clear definitions of treatment response. This distinction is essential for preventing promising biological observations from being prematurely interpreted as clinically established biomarkers.

4.6. Integrated Evidence and Remaining Research Gaps

The evidence synthesized in this review indicates that the relationship between the gut microbiome and autoimmune hepatitis is multidimensional and involves interactions among microbial ecology, intestinal barrier integrity, microbial metabolism, and host immune regulation. Rather than functioning through a single pathway, these components appear to form an interconnected biological network in which alterations at one level may influence processes at several other levels [7,8,11].

At the microbial level, dysbiosis has been associated with changes in the intestinal ecosystem that may interfere with normal host-microbiome homeostasis. These alterations can affect both the structural composition and functional activity of the microbial community. The resulting changes may influence epithelial integrity and the availability of microbial-derived signaling molecules, thereby extending the consequences of dysbiosis beyond the intestinal compartment [3,6].

At the barrier level, impaired intestinal integrity represents a potentially important link between microbial alterations and hepatic inflammation. Increased permeability can facilitate exposure of the portal circulation and hepatic immune system to microbial components. Experimental evidence involving the gut-liver axis suggests that this process may activate inflammatory pathways and contribute to persistence of autoimmune hepatic injury [5,6].

Table 6. Integrated Evidence Across the Gut Microbiome–Autoimmune Hepatitis Continuum

Biological level	Principal finding	Relationship with disease	Potential relationship with treatment response
Microbial ecology	Dysbiosis and altered microbial communities	Associated with disrupted immune homeostasis	May modify the biological environment of treatment
Intestinal barrier	Increased permeability and barrier dysfunction	Facilitates microbial-host interaction	May sustain inflammatory stimulation despite treatment
Microbial metabolism	Altered production of immune-active metabolites	Influences immune regulation	May modify immune responsiveness
Innate immunity	Activation of microbial-sensing inflammatory pathways	Promotes hepatic inflammation	May influence persistence of inflammatory activity
Adaptive immunity	Altered T-cell regulation	Contributes to autoimmune activity	May affect response to immunosuppressive therapy
Microbiome modulation	Changes in microbial ecosystem following intervention	Can reduce experimental inflammation	Potential complementary therapeutic strategy
Clinical translation	Emerging microbial signatures	Potential disease characterization	Predictive value remains unvalidated

At the metabolic level, microbiome-derived metabolites may provide an additional mechanism for communication between intestinal microorganisms and host immunity. Altered production of biologically active metabolites, particularly tryptophan-derived compounds, can influence immune signaling and T-cell activity. This provides a functional explanation for why microbial metabolic activity may be clinically relevant even when taxonomic changes alone appear modest [11,12].

At the immune level, microbiome-associated signals may affect both innate and adaptive immune responses. Interactions involving T-cell populations, including follicular helper T cells, provide a potential mechanism through which intestinal microbial alterations can influence systemic immune regulation and hepatic autoimmunity [2,4,10]. The convergence of these pathways suggests that treatment response may be influenced by the broader immunological environment established by the gut-liver axis.

Table 6 demonstrates that the available evidence converges on a common biological framework but does not yet provide sufficient evidence for a single predictive model. The strongest evidence concerns mechanistic relationships, whereas evidence directly linking baseline microbiome characteristics to subsequent treatment outcomes in human patients remains comparatively limited.

One of the most important research gaps is the absence of sufficiently standardized definitions of microbiome-associated treatment response. Different investigations may evaluate biochemical improvement, inflammatory activity, histological changes, or other outcomes at different time points. Without standardized clinical endpoints, it is difficult to determine whether microbial signatures identified across studies represent the same biological phenomenon.

A second gap concerns temporal directionality. Cross-sectional studies can demonstrate associations between microbial characteristics and disease status, but they cannot determine whether dysbiosis precedes disease activity or develops as a consequence of hepatic inflammation or treatment. Longitudinal sampling is therefore essential. Repeated assessment of microbiome composition and function before treatment initiation and throughout therapy could help establish whether specific microbial changes predict therapeutic response or simply accompany it.

A third gap is the limited integration of microbial composition with microbial function. Sequencing-based identification of bacterial taxa provides important information about community structure, but taxonomic abundance does not necessarily indicate metabolic activity. Incorporating microbial metabolites into future studies may therefore provide a more functionally informative representation of the microbiome [11,12].




Figure 6. Integrated Conceptual Model of Microbiome Influence on Treatment Response

A fourth gap concerns the limited clinical validation of microbiome-targeted interventions. Probiotic, synbiotic, and other microbiome-modulating strategies have produced encouraging results in experimental models [1,5,9]. However, experimental improvement in hepatic inflammation does not establish that similar interventions will improve remission rates, reduce relapse, or alter long-term outcomes in patients with autoimmune hepatitis.

Figure 6 integrates the principal findings of the review into a single multidimensional framework. It illustrates that treatment response may emerge from interactions between microbial ecology and host immune mechanisms rather than from a single microbial characteristic. The model should therefore be regarded as a synthesis of current biological evidence rather than a validated clinical prediction model.

The evidence also suggests that future research should move beyond simple comparisons between patients with and without autoimmune hepatitis. More informative designs would compare microbial characteristics across clinically defined treatment-response phenotypes while controlling for treatment exposure and major host-related factors. Such studies could determine whether microbial differences are associated specifically with response status rather than simply reflecting the presence of disease.

Another important priority is the identification of functionally meaningful microbial signatures. Rather than focusing exclusively on bacterial abundance, future studies could integrate taxonomic profiles with microbial gene functions, metabolomic measurements, intestinal permeability indicators, and immune-cell phenotypes. Such multidimensional profiling may provide a more reliable representation of the biological pathways that influence therapeutic response.

The current evidence further suggests that the gut microbiome should not be considered independently of conventional clinical variables. Treatment response in autoimmune hepatitis is determined by a complex interaction of disease activity, immune regulation, pharmacological exposure, and patient-specific biological characteristics. Microbiome-related measures may therefore be most useful as complementary variables within a broader predictive framework rather than as standalone biomarkers.

Overall, the integrated evidence supports a coherent biological association between gut microbiome dysbiosis and autoimmune hepatitis and provides several plausible mechanisms through which the microbiome could influence treatment response. Nevertheless, the evidence remains stronger for mechanistic plausibility than for validated clinical prediction. Establishing clinical utility will require prospective, longitudinal, standardized studies capable of distinguishing causal microbial features from secondary changes associated with disease or treatment.

5- Discussion

The evidence synthesized in this review supports a multidimensional relationship between the gut microbiome and autoimmune hepatitis, extending from intestinal microbial ecology to hepatic immune regulation and potentially to variability in treatment response. The central implication is that gut microbiome dysbiosis should not be considered merely an accompanying feature of autoimmune hepatitis. Instead, alterations in microbial composition, intestinal barrier function, microbial metabolism, and immune signaling appear to form interconnected components of the gut-liver axis that may influence the biological environment in which autoimmune hepatic inflammation develops and responds to therapy [3,6-8].

One of the most important observations is the convergence of evidence across different biological levels. Studies examining microbial alterations have identified changes associated with autoimmune hepatic inflammation, while mechanistic investigations have demonstrated that disruption of microbial homeostasis can affect intestinal permeability and immune regulation [3,6]. These findings are strengthened by experimental interventions showing that modification of the intestinal microbial environment can attenuate inflammatory activity [1,5,9]. The convergence of observational and experimental evidence increases the biological plausibility of a functional relationship, although it does not establish that the same mechanisms operate with equivalent magnitude in human patients.

The intestinal barrier appears to occupy a particularly important position within this framework. A healthy intestinal barrier limits systemic exposure to microbial components while allowing physiological communication between the microbiome and host. When barrier integrity is impaired, microbial products may reach the portal circulation and interact directly with hepatic immune cells. Activation of innate immune pathways, including TLR4-associated signaling and downstream inflammatory mechanisms, may subsequently contribute to amplification of hepatic inflammation [5,6]. This mechanism provides a plausible explanation for how an alteration initially localized to the intestine can influence an autoimmune process occurring within the liver.

The findings concerning microbial metabolites add another dimension to this model. Microbial metabolism generates a wide range of biologically active compounds capable of modifying host signaling. Tryptophan-derived metabolites are particularly relevant because their interaction with the aryl hydrocarbon receptor can influence immune-cell activity and contribute to the regulation of inflammatory responses [12]. This observation suggests that microbiome assessment based exclusively on bacterial abundance may overlook important functional information. Two microbial communities with different taxonomic profiles may potentially produce similar metabolites, while relatively similar microbial communities may generate different metabolic outputs depending on environmental and host factors.

The interaction between microbiota and adaptive immunity is also relevant to understanding treatment response. Evidence concerning follicular helper T cells suggests that microbial modulation may influence immune-cell populations involved in autoimmune regulation [2]. Other studies have demonstrated relationships between microbial alterations and T-cell-mediated hepatic injury [4,10]. These observations provide a mechanistic basis for considering the microbiome as a potential modifier of immunological responsiveness rather than simply a marker of disease activity.

The potential interaction with corticosteroid therapy is particularly noteworthy. Evidence indicating that Lactobacillus-associated microbiome modulation can enhance prednisone-related effects suggests that microbial factors may influence the therapeutic environment in which immunosuppressive drugs operate [2]. However, this observation should be interpreted cautiously. Enhancement of treatment-associated effects in an experimental setting

does not establish that a particular bacterial intervention will improve remission or long-term outcomes in patients. It nevertheless identifies a biologically testable hypothesis for future clinical investigation.

The evidence concerning probiotics and synbiotics similarly supports the possibility that microbiome-directed interventions could complement conventional immunosuppressive therapy. Experimental studies have reported changes in microbial composition, intestinal permeability, and inflammatory signaling following microbiome modulation [1,5]. The significance of these findings lies less in establishing an immediate therapeutic recommendation and more in demonstrating that the gut-liver axis is potentially modifiable. The microbiome may therefore represent a biological pathway through which adjunctive strategies could eventually be developed.

At present, however, the clinical evidence does not support the use of microbiome characteristics as established predictors of treatment response. Several factors contribute to this limitation. First, the available human evidence remains relatively limited compared with the mechanistic literature. Second, microbiome composition is highly sensitive to environmental and host-related variables. Diet, medication exposure, geographic characteristics, and other factors can modify microbial communities and potentially obscure disease-specific patterns [7,8,13]. Third, the definition of treatment response varies between studies, limiting comparability across investigations.

The temporal relationship between dysbiosis and therapeutic response represents another major unresolved issue. If microbial changes occur before treatment failure or relapse, they may have predictive value. Conversely, if the changes develop only after treatment initiation, they may represent treatment-associated effects rather than predictors. A third possibility is that disease activity, treatment, and microbiome composition influence one another simultaneously. Distinguishing these alternatives requires longitudinal studies rather than single time-point comparisons.

The available experimental evidence also requires careful interpretation. Animal models have been essential for identifying potential causal pathways and testing microbiome-targeted interventions [1,3-5,9]. Nevertheless, experimental autoimmune hepatitis does not reproduce all biological and clinical characteristics of human disease. Differences in immune systems, microbial ecology, diet, genetic background, and treatment exposure can influence the extent to which experimental findings translate into clinical settings. Accordingly, animal evidence should primarily be regarded as mechanistic support rather than direct evidence of clinical effectiveness.

A further consideration is the distinction between microbial composition and microbial function. Current research frequently emphasizes taxonomic profiling, but the biological consequences of the microbiome depend substantially on metabolic activity and host-microbe interactions. The growing evidence concerning microbial metabolites suggests that functional measurements may be particularly valuable [11,12]. Future studies combining metagenomic, metabolomic, immunological, and clinical data may therefore provide a more comprehensive assessment of microbiome-related treatment response.

The potential clinical application of these findings is best conceptualized as an integrated biomarker approach. Instead of using an individual bacterial taxon as a standalone predictor, future models could combine microbial composition with metabolite profiles, intestinal barrier markers, immune-cell characteristics, treatment exposure, and longitudinal biochemical outcomes. Such a multidimensional approach would better reflect the biological complexity of autoimmune hepatitis and could help distinguish disease-associated microbial changes from features specifically associated with therapeutic response.

The literature also raises an important question concerning causality. The presence of dysbiosis in autoimmune hepatitis does not necessarily mean that dysbiosis initiates the disease. Altered hepatic metabolism, inflammation, dietary changes, and medications may themselves affect the intestinal microbial ecosystem. Experimental studies demonstrating that manipulation of the microbiome can alter hepatic inflammation provide stronger evidence for biological involvement [1,5,9], but the precise causal sequence in human disease remains incompletely defined.

From a translational perspective, the most important next step is therefore not simply to identify additional microbial differences, but to determine which microbial characteristics have reproducible temporal and functional relationships with treatment outcomes. Prospective studies should ideally obtain microbiome and metabolomic measurements before therapy and at standardized intervals thereafter, while simultaneously documenting treatment exposure, biochemical response, relapse, and relevant host factors. Such designs would help determine whether microbiome alterations can provide information beyond conventional clinical and biochemical indicators.

The emerging evidence also supports a shift from a purely taxonomic view of the microbiome toward a systems-level interpretation. The gut microbiome, intestinal barrier, microbial metabolites, and immune system operate as an interconnected network. Alteration at one level may produce secondary changes at others, making it difficult to attribute treatment response to an individual microbial factor. A systems-level framework may therefore be more appropriate for understanding the contribution of the microbiome to autoimmune hepatitis.

Overall, the current evidence provides a coherent mechanistic rationale for a relationship between gut microbiome dysbiosis and treatment response in autoimmune hepatitis. The strongest support concerns the interaction among microbial imbalance, intestinal barrier dysfunction, microbial metabolites, and immune regulation. Evidence for direct clinical prediction remains less mature. The microbiome should consequently be viewed as a promising biological and translational domain rather than an established clinical determinant of treatment selection. Further prospective and longitudinal research is required to determine whether microbiome-derived information can ultimately improve treatment stratification and personalized management of autoimmune hepatitis.

6- Conclusion

The available evidence supports a biologically plausible and increasingly recognized relationship between gut microbiome dysbiosis and autoimmune hepatitis. Alterations in microbial composition and function may influence intestinal barrier integrity, microbial translocation, production of immune-active metabolites, and regulation of innate and adaptive immune responses. These interconnected mechanisms provide a potential explanation for how intestinal microbial disturbances may contribute to the persistence and variability of hepatic autoimmune inflammation.

Evidence from experimental studies further indicates that modification of the gut microbiome can influence inflammatory activity and pathways relevant to immunosuppressive treatment. Interactions involving Lactobacillus, microbial metabolites, T-cell regulation, and inflammatory signaling suggest that the microbiome may influence the biological context in which established therapies act. Nevertheless, much of the current mechanistic evidence originates from experimental models, and direct clinical evidence linking specific microbial characteristics with treatment response remains limited.

At present, the gut microbiome cannot be considered a validated standalone biomarker for predicting treatment response or selecting therapy in autoimmune hepatitis. The considerable heterogeneity of microbial profiles, treatment exposure, study designs, and clinical endpoints further limits immediate clinical translation. Future research should prioritize prospective longitudinal studies integrating microbial composition, microbial metabolites, intestinal barrier function, immune phenotypes, and standardized treatment outcomes.

A multidimensional approach may ultimately provide greater clinical value than reliance on individual microbial taxa. Establishing reproducible microbiome-associated signatures and determining their independent contribution to treatment response could open new opportunities for patient stratification and adjunctive therapeutic strategies. Until such evidence becomes available, the gut microbiome should be regarded primarily as a promising mechanistic and translational target in the evolving understanding of autoimmune hepatitis.

References

1. Liu Q, Tian H, Kang Y, Tian Y, Li L, Kang X, et al. Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability. J Nutr Biochem. 2021;98:108863.
2. Ma L, Zhang L, Zhuang Y, Ding Y, Chen J. Lactobacillus improves the effects of prednisone on autoimmune hepatitis via gut microbiota-mediated follicular helper T cells. Cell Commun Signal. 2022;20(1):83.
3. Centa M, Weinstein EG, Clemente JC, Faith JJ, Fiel MI, Lyallpuri R, et al. Impaired central tolerance induces changes in the gut microbiota that exacerbate autoimmune hepatitis. J Autoimmun. 2022;128:102808.
4. Pandey SP, Bender MJ, McPherson AC, Phelps CM, Medina Sanchez L, Rana M, et al. Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell Host Microbe. 2022;30(7):1003-1019.e10.
5. Kang Y, Kuang X, Yan H, Ren P, Yang X, Liu H, et al. A novel synbiotic alleviates autoimmune hepatitis by modulating the gut microbiota-liver axis and inhibiting the hepatic TLR4/NF-κB/NLRP3 signaling pathway. mSystems. 2023;8(2):e01127-22.
6. Lin H, Lin J, Pan T, Li T, Jiang H, Fang Y, et al. Polymeric immunoglobulin receptor deficiency exacerbates autoimmune hepatitis by inducing intestinal dysbiosis and barrier dysfunction. Cell Death Dis. 2023;14(1):68.
7. Li L, Kang Y. The gut microbiome and autoimmune hepatitis: implications for early diagnostic biomarkers and novel therapies. Mol Nutr Food Res. 2023;67(24):e2300043.
8. Sun C, Zhu D, Zhu Q, He Z, Lou Y, Chen D. The significance of gut microbiota in the etiology of autoimmune hepatitis: a narrative review. Front Cell Infect Microbiol. 2024;14:1337223.
9. Yang H, Liu Q, Liu H, Kang X, Tian H, Kang Y, et al. Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut microbiota. Hepatol Commun. 2024;8(4):e0381.
10. Wu Q, Ge Z, Lv C, He Q. Interacting roles of gut microbiota and T cells in the development of autoimmune hepatitis. Front Immunol. 2025;16:1584001.
11. Zhang X, Wan L, Zheng Y, Ai Y. Gut barrier, microbial metabolites, and immune homeostasis in autoimmune hepatitis: from molecular mechanisms to strategies. Front Biosci (Landmark Ed). 2025;30(5):27747.
12. Li B, Liang X, Li Y, Wang R, Wei Y, Liu Q, et al. Tryptophan catabolites from microbiota ameliorate immune-mediated hepatitis through activating aryl hydrocarbon receptor of T cells. Gut Microbes. 2025;17(1):2557979.
13. Iftikhar F, Iftikhar A, Khalid M, Talha M, Waafira A. Gut microbial signatures in autoimmune hepatitis: unlocking diagnostic and therapeutic potential. Ann Med Surg (Lond). 2025;87(10):6868-6869.